Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia

References

• Decramer M Janssens W Miravitlles M Chronic obstructive pulmonary disease Lancet 2012 379 1341 1351 22314182
   PubMed Web of Science ®Google Scholar
• Hunninghake GW Crystal RG Cigarette smoking and lung destruction. Accumulation of neutrophils in the lung of cigarette smokers Am Rev Respir Dis 1983 128 833 838 6556892
   PubMed Web of Science ®Google Scholar
• Kanazawa H Kurihara N Hirata K Fujimoto S Takeda T The role of free radicals and neutrophil elastase in development of pulmonary emphysema Intern Med 1992 31 857 860 1333306
   PubMed Web of Science ®Google Scholar
• Barnes PJ Shapiro SD Pauwels RA Chronic obstructive pulmonary disease: molecular and cellular mechanisms Eur Respir J 2003 22 672 688 14582923
   PubMed Web of Science ®Google Scholar
• Cosio MG Majo J Cosio MG Inflammation of the airways and lung parenchyma in COPD: role of T cells Chest 2002 121 160S 165S 12010846
   PubMed Web of Science ®Google Scholar
• Bhowmik A Seemungal TA Sapsford RJ Wedzicha JA Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbation Thorax 2000 55 114 120 10639527
   PubMed Web of Science ®Google Scholar
• Fry AM Shay DK Holman RC Curns AT Anderson LJ Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988–2002 JAMA 2005 294 2712 2719 16333006
   PubMed Web of Science ®Google Scholar
• Farr BM Bartlett CL Wadsworth J Miller DL Risk factors for community-acquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group Respir Med 2000 94 954 963 11059948
   PubMed Web of Science ®Google Scholar
• Restrepo MI Mortensen EM Pugh JA Anzueto A COPD is associated with increased mortality in patients with community-acquired pneumonia Eur Respir J 2006 28 346 351 16611653
   PubMed Web of Science ®Google Scholar
• Holguin F Folch E Redd SC Mannino DM Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001 Chest 2005 128 2005 2011 16236848
   PubMed Web of Science ®Google Scholar
• Szafranski W Cukier A Ramirez A Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur Respir J 2003 21 74 81 12570112
   PubMed Web of Science ®Google Scholar
• Spencer S Calverley PMA Burge PS Jones PW Impact of preventing exacerbation on deterioration of health status in COPD Eur Respir J 2004 23 698 702 15176682
   PubMed Web of Science ®Google Scholar
• Calverley P Pauwels R Vestbo J Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial Lancet 2003 361 449 456 12583942
   PubMed Web of Science ®Google Scholar
• Vestbo J Hurd SS Agusti AG Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 2013 187 347 365 22878278
   PubMed Web of Science ®Google Scholar
• Global initiative for chronic Obstructive Lung Disease Global Strategy for Diagnosis, Management, and Prevention of COPD Bethesda (MD) GOLD 2013 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf Accessed April 12, 2014
   Google Scholar
• Drummond MB Dasenbrook EC Pitz MW Murphy DJ Fan E Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis JAMA 2008 300 2407 2416 19033591
   PubMed Web of Science ®Google Scholar
• Singh S Amin AV Loke YK Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis Arch Intern Med 2009 169 219 229 19204211
   PubMed Web of Science ®Google Scholar
• Ernst P Gonzalez AV Brassard P Suissa S Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia Am J Respir Crit Care Med 2007 176 162 166 17400730
   PubMed Web of Science ®Google Scholar
• Calverley PM Anderson JA Celli B Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 2007 356 775 798 17314337
   PubMed Web of Science ®Google Scholar
• Welte T Miravitlles M Hernandez P Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 2009 180 741 750 19644045
   PubMed Web of Science ®Google Scholar
• Sin DD Tashkin D Zhang X Budesonide and the risk of pneumonia: a meta-analysis of individual patient data Lancet 2009 374 712 719 19716963
   PubMed Web of Science ®Google Scholar
• Rennard SI Tashkin DP McElhattan J Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial Drugs 2009 69 549 565 19368417
   PubMed Web of Science ®Google Scholar
• Tashkin DP Rennard SI Martin P Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial Drugs 2008 68 1975 2000 18778120
   PubMed Web of Science ®Google Scholar
• Chen D Restrepo MI Fine MJ Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia Am J Respir Crit Care Med 2011 184 312 316 21512168
   PubMed Web of Science ®Google Scholar
• Cheng SL Wang HC Cheng SJ Yu CJ Elevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy BMC Pulm Med 2011 11 46 21962211
   PubMed Web of Science ®Google Scholar
• Jones PW Harding G Berry P Wiklund I Chen WH Kline Leidy N Development and first validation of the COPD Assessment Test Eur Respir J 2009 34 648 654 19720809
   PubMed Web of Science ®Google Scholar
• Hogg JC Chu F Utokaparch S The nature of small-airway obstruction in chronic obstructive pulmonary disease N Engl J Med 2004 350 2645 2653 15215480
   PubMed Web of Science ®Google Scholar
• Ozol D Aysan T Solak ZA Mogulkoc N Veral A Sebik F The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients Respir Med 2005 99 1494 1500 15946834
   PubMed Web of Science ®Google Scholar
• MacRedmond RE Greene CM Dorscheid DR McElvaney NG O’Neill SJ Epithelial expression of TLR4 is modulated in COPD and by steroid, salmeterol and cigarette smoke Respir Res 2007 8 84 18034897
   PubMed Web of Science ®Google Scholar
• Zanini A Chetta A Saetta M Bronchial vascular remodeling in patients with COPD and its relationship with inhaled steroid treatment Thorax 2009 64 1019 1024 19736178
   PubMed Web of Science ®Google Scholar
• Sims MW Tal-Singer RM Kierstein S Chronic obstructive pulmonary disease and inhaled steroid alter surfactant protein D (SP-D) levels: a cross-sectional study Respir Res 2008 9 13 18226251
   PubMed Web of Science ®Google Scholar
• Yawn BP Li Y Tian H Zhang J Arcona S Kahler KH Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis Int J Chron Obstruct Pulmon Dis 2013 8 295 304 23836970
   PubMed Web of Science ®Google Scholar
• Thornton Snider J Luna Y Wong KS Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD Curr Med Res Opin 2012 28 1959 1967 23098081
   PubMed Web of Science ®Google Scholar
• Ryan M Suaya JA Chapman JD Stason WB Shepard DS Thomas CP Incidence and cost of pneumonia in older adults with COPD in the United States PLoS One 2013 8 e75887 24130749
   PubMed Web of Science ®Google Scholar
• Suissa S Patenaude V Lapi F Ernst P Inhaled corticosteroids in COPD and the risk of serious pneumonia Thorax 2013 68 1029 1036 24130228
   PubMed Web of Science ®Google Scholar
• Ferguson GT Anzueto A Fei R Emmett A Knobil K Kalberg C Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations Respir Med 2008 102 1099 1108 18614347
   PubMed Web of Science ®Google Scholar
• Anzueto A Ferguson GT Feldman G Effect of fluticasone propionate/samleterol (250/50) on COPD exacerbation and impact on patient outcomes COPD 2009 6 320 329 19863361
   PubMedGoogle Scholar
• Malo de Molina R Mortensen EM Restrepo MI Copeland LA Pugh MJ Anzueto A Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia Eur Respir J 2010 36 751 757 20413535
   PubMed Web of Science ®Google Scholar
• Singanayagam A Chalmers JD Akram AR Hill AT Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia Eur Respir J 2011 38 36 41 21429980
   PubMed Web of Science ®Google Scholar
• Kim JH Park JS Kim KH Jeong HC Kim EK Lee JH Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD Chest 2013 143 1018 1024 23079688
   PubMed Web of Science ®Google Scholar
• Lee CH Kim K Hyun MK Jang EJ Lee NR Yim JJ Use of inhaled corticosteroids and the risk of tuberculosis Thorax 2013 68 1105 1113 23749841
   PubMed Web of Science ®Google Scholar
• Suissa S Kezouh A Ernst P Inhaled corticosteroids and the risks of diabetes onset and progression Am J Med 2010 123 1001 1006 20870201
   PubMed Web of Science ®Google Scholar
• O’Byrne PM Rennard S Gerstein H Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids Respir Med 2012 106 1487 1493 22902134
   PubMed Web of Science ®Google Scholar
• Dendukuri N Blais L LeLorier J Inhaled corticosteroids and the risk of diabetes among the elderly Br J Clin Pharmacol 2002 54 59 64 12100226
   PubMed Web of Science ®Google Scholar
• Blackburn D Hux J Mamdani M Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly J Gen Intern Med 2002 17 717 720 12220369
   PubMed Web of Science ®Google Scholar